In studying the relationship between STAT3 and CSCs, Polyak and colleagues found that the IL-6/JAK2/Stat3 pathway is preferentially active in CD44+CD24− stem-enriched breast cancer cells, where it is required for their growth (Marotta et al., 2011). The gene discussed is CD44; the disease is breast cancer.